Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Chimeric Antigen Receptor (CAR) T Cells”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Testing effectiveness (Phase 2)Study completedNCT03097770
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 100
Early research (Phase 1)Looking for participantsNCT05098613
What this trial is testing

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Who this might be right for
Non-Hodgkin LymphomaB-cell Non-Hodgkin Lymphoma (B-NHL)Mantle Cell Lymphoma (MCL)+1 more
University of Colorado, Denver 68
Testing effectiveness (Phase 2)Looking for participantsNCT06081478
What this trial is testing

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB-cell LymphomaDiffuse Large B Cell Lymphoma
Beijing Tongren Hospital 100
Testing effectiveness (Phase 2)UnknownNCT06503094
What this trial is testing

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Early research (Phase 1)UnknownNCT03271515
What this trial is testing

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Who this might be right for
LeukemiaLymphoma
Beijing Doing Biomedical Co., Ltd. 20
Early research (Phase 1)Looking for participantsNCT06559189
What this trial is testing

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver 53
Testing effectiveness (Phase 2)UnknownNCT03185494
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 30
Not applicableStudy completedNCT06415656
What this trial is testing

VitalTraq for the Detection of CRS

Who this might be right for
Hematologic Malignancy
Duke University 32
Testing effectiveness (Phase 2)UnknownNCT04553393
What this trial is testing

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Who this might be right for
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
Chinese PLA General Hospital 80
Very early researchNot Yet RecruitingNCT07546630
What this trial is testing

Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma

Who this might be right for
Relapsed/Refractory B-Cell Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences 20
Early research (Phase 1)Looking for participantsNCT07193628
What this trial is testing

B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma

Who this might be right for
Refractory GlioblastomaRecurrent Glioblastoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 14
Large-scale testing (Phase 3)Looking for participantsNCT07648264
What this trial is testing

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Who this might be right for
Secondary Immune Deficiency
CSL Behring 63
Early research (Phase 1)Not Yet RecruitingNCT07701889
What this trial is testing

Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

Who this might be right for
Hematologic Diseases
Roswell Park Cancer Institute 21
Early research (Phase 1)Active Not RecruitingNCT04007029
What this trial is testing

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
CD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic Leukemia+11 more
Jonsson Comprehensive Cancer Center 24
Early research (Phase 1)Looking for participantsNCT06285279
What this trial is testing

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

Who this might be right for
Lupus NephritisANCA-associated VasculitisMembranous Nephropathy - PLA2R Induced+1 more
Nanjing University School of Medicine 24
Early research (Phase 1)UnknownNCT03463928
What this trial is testing

A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

Who this might be right for
B Cell Leukemia
Chinese PLA General Hospital 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04499573
What this trial is testing

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

Who this might be right for
B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 50
Not applicableLooking for participantsNCT07359014
What this trial is testing

Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapse Multiple Myeloma
Second Affiliated Hospital, Zhejiang University, School of Medicine 25
Very early researchUnknownNCT04303247
What this trial is testing

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Who this might be right for
B-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Xinqiao Hospital of Chongqing 30
Testing effectiveness (Phase 2)Looking for participantsNCT06735495
What this trial is testing

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Next Page